Mohammed M. Abadleh

Synthesis, in silico studies, and in vitro evaluation of novel isoindigo inhibitors targeting wild-type and D835Y mutant FLT3

FMS-like tyrosine kinase 3 (FLT3) is a validated therapeutic target, but resistance mutations such as D835Y compromise its therapeutic utility by conferring resistance to existing inhibitors and limiting therapeutic options in FLT3-driven cancers, such as Acute Myeloid Leukemia (AML). In order to address this challenge...